Sign Up
Ready to replace complexity with clarity?
Answer your real world compliance questions (limited time) and save thousands in legal fees and avoided fines.
Automate Compliance TodayUS states A to Z: marijuana, THCA, delta-8, delta-9, delta-10, HHC
State-by-state mapMost read countries: marijuana, CBD and hemp status
All countries on the globeSubstances: status in every state for each one
Compare all substancesFederal hemp redefinition: P.L. 119-103, div. B, sec. 2019
Nov 12, 2026
Applies only to cannabinoids the plant cannot naturally produce.
Dec 11, 2026
The total-THC test, the 0.4 mg per container cap and the exclusion of converted cannabinoids start.
Latest regulatory actions, updated daily
All regulatory actionsHeadlines and the first four sentences are free. Full write-ups, impact reasoning and the archive are for members.
Member · $99/mo
Every rule change, the day it is made.
The price will rise. Join now and $99 a month stays your rate for life.
Become a memberOr read free: every action opens 30 days after it is published. Sign in with email
By topic
Licensing and permitsPackaging and labelingLab testing and QARetail complianceAdvertising and marketingBanking and paymentsTaxesShipping and logisticsTravel and transportLitigationSOPsFor your role
Regulators and agenciesBrands and operatorsRetailers and smoke shopsCultivatorsProcessorsLawyers and complianceInvestorsConsumers and travelersThe Regulator Brief · newsletter
Every rule change that matters, every Monday.
Free: the Monday brief, and every action 30 days after it is published.
Members: the paid weekly, daily alerts and every write-up.
Read by regulators, operators, lawyers and founders.
Cannabis lawyers
Licensed by state. Listings are not endorsements.
By state
Software and services
Compared by fit, never ranked.
Categories
For companies and firms
Be the listing operators and regulators find.
Software and services
Verified, $49/mo: domain-verified badge, your website link, a quote.
Featured, from $399/mo: labeled Featured in your category, monthly release notes.
Lawyers and firms
Claimed, $75/yr: Claimed badge and your firm's website link.
Featured, $199/mo: labeled Featured on your profile.
Claim your companyClaim a lawyer listingPlacements, flat monthly fee
State and country page sponsorshipsExclusive slot on a legality page and its postsRegulator Brief sponsorshipPresenting sponsor or mid-issue banner, free editionMember brief sponsor slotThe paid weekly, read by members onlyFeatured directory placementLabeled Featured in a software categoryCategory sponsorshipOwn one directory category across the sitePaid guest postsLabeled Paid guest post, sponsored linksWrite and partner
Pitch a paid guest postRead guest postsBecome an affiliateSend a tip or correctionContact the teamWho reads it
Regulators at federal, state and county agencies, plus the operators, lawyers and founders they regulate.
Get the media kitSee open placementsSubstances
US states, map and A to ZCountriesFederal hemp 2026: Nov 12 and Dec 11Compound index, every stateTravelling with cannabis or hempMembers get the daily alert email and every full write-up the morning it is published. Every action is free to read 30 days later.
For your role
All news and analysisGuidesAnalysisFAQsTemplates and SOPsCourt filing recapsNews by state and countrySoftware and services: Verified $49/mo, Featured from $399/mo. Lawyers and firms: Claimed $75/yr, Featured $199/mo. Listings are not endorsements.
Regulatory journalism, not legal advice. How we report

The DEA's long-awaited hearing on moving marijuana from Schedule I to Schedule III of the Controlled Substances Act opened June 29 and, per the administrative law judge's schedule, must conclude no later than July 15. Week one put the government's scientific case on the record — and gave opponents their first sustained chance to attack it. For operators, the next seven days will shape the evidentiary record that determines whether Schedule III survives its all-but-certain court challenges.
Status: for where marijuana rescheduling stands now, see the marijuana rescheduling tracker.
The proceeding is the formal, on-the-record phase of the rescheduling rulemaking. The DEA's hearing notice set presentations from June 29 through July 14, with the hearing to conclude by July 15. The government — DEA, defending its own proposed rule — presents witnesses supporting the Schedule III recommendation, while seven designated participants, all of whom oppose rescheduling, are permitted to present evidence and cross-examine.
That alignment is the structural oddity of this hearing: the agency that spent decades defending Schedule I is now the party defending marijuana's medical value, while prohibition-oriented groups sit across the aisle as the only cross-examiners.
The government opened with Dominic Chiapperino, director of the controlled substance staff at FDA's Center for Drug Evaluation and Research, who walked through the agency's finding that marijuana has a currently accepted medical use and a lower abuse potential than Schedule I and II comparators.
Cross-examination centered on the FDA's revised "two-factor" test for currently accepted medical use. Opponents attacked the analysis on day two, pressing the FDA on why it departed from the older five-factor framework — and drawing an acknowledgment that cannabis could not have satisfied the prior test. That admission is the fulcrum of the opposition's legal theory: if the medical-use finding required a new test, the finding is vulnerable on review. Cannabis Business Times reported that DEA's counsel came out aggressively in defense of the two-factor framework.
Outside the hearing room, the Justice Department filed a brief opposing an attempt by a drug-testing trade group and a pharmaceutical company to pause the proceedings, arguing the movants' real stake is financial: they profit from marijuana remaining in Schedule I. The government defending its rescheduling rule against industry incumbents is a posture worth noting — it signals DOJ intends to see the rule through the administrative process rather than let it stall.
The second week belongs largely to the designated participants. Smart Approaches to Marijuana began its presentation July 6; the same day, Harvard Medical School psychobiology professor Bertha Madras — a longtime rescheduling opponent — testified that products sold through state dispensaries are not developed under pharmaceutical standards. Additional participants, including victim-advocacy and state-level witnesses, are scheduled through July 14.
Expect the opposition to hammer three themes: the two-factor test's novelty, the gap between dispensary products and FDA-approved drugs, and impaired-driving data. None of these must persuade the administrative law judge to block rescheduling outright — the goal is building a record for appeal.
The hearing does not end with a scheduling decision. It closes the evidentiary record on which the ALJ will issue a recommended ruling; the DEA administrator then issues a final rule, and litigation is widely expected regardless of outcome. We covered what was at stake when the hearing opened and the participants and notice-of-intent filings earlier in the cycle.
For operators, the practical question is §280E. Schedule III would end the tax code's disallowance of ordinary business deductions for plant-touching companies — the single largest financial swing in the industry. Some operators have already filed refund claims or adjusted reserves in anticipation; the §280E stay motion we covered previously shows how contested that timing question remains. Nothing in week one changes the prudent posture: model both scenarios, document reserve decisions, and make no irreversible tax elections until a final rule is effective. Talk to your counsel and tax advisors before acting.
FDA's Dominic Chiapperino testified on marijuana's medical value and relative abuse potential; opponents pressed him on the agency's revised two-factor medical-use test.
A revised FDA analysis for determining "currently accepted medical use." An FDA official acknowledged during cross-examination that cannabis could not have passed the agency's prior five-factor test.
Presentations run through July 14, and the hearing concludes no later than July 15, 2026.
No. It builds the evidentiary record for the administrative law judge's recommendation. A final rule comes later, and litigation is expected either way.
DOJ opposed a drug-testing trade group and pharma company's motion to pause rescheduling, arguing they profit from marijuana remaining in Schedule I.
This article is for informational purposes only and is not legal advice. Consult your counsel before making compliance or tax decisions.